Ribociclib plus letrozole in patients with hormone receptor-positive, HER2-negative advanced breast cancer with no prior endocrine therapy: subgroup safety analysis from the phase 3b CompLEEment-1 trial
By:
Authors
Simona Borstnar
Department of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
Marketa Palacova
Clinic of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic
Aleksandra Łacko
Department of Clinical Oncology, Wroclaw University of Medicine, Wrocław, Poland, and Breast Unit, Lower Silesian Oncology Centre, Wroclaw, Poland
Constanta Timcheva
Medical Oncology Clinic, Multiprofile Hospital for Active Treatment “Nadezhda” Sofia, Sofia, Bulgaria
Einav Nili Gal-Yam
Talpiot medical leadership program, Institute of Oncology, Chaim Sheba Medical Center, Tel-Hashomer; affiliated to the Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Konstantinos Papazisis
Euromedica General Clinic of Thessaloniki, Thessaloniki, Greece
Juraj Beniak
Regional Cancer Center, Poprad, Slovakia
Pavol Kudela
Novartis Slovakia s.r.o, Bratislava, Slovakia
Gábor Rubovszky
Department of Oncological Internal Medicine and Clinical Pharmacology, National Institute of Oncology, Budapest, Hungary
Language: English
Page range: 238 - 247
Submitted on: Feb 25, 2022
Accepted on: Apr 8, 2022
Published on: May 17, 2022
Published by: Association of Radiology and Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year
Keywords:
Related subjects:
© 2022 Simona Borstnar, Marketa Palacova, Aleksandra Łacko, Constanta Timcheva, Einav Nili Gal-Yam, Konstantinos Papazisis, Juraj Beniak, Pavol Kudela, Gábor Rubovszky, published by Association of Radiology and Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.